Dr. Paden King is currently a researcher at the National Cancer Institute (NCI), where he works under the direction of Dr. Freddy Escorcia to develop novel radioconjugates for cancer imaging and therapy. These research efforts include the investigation of Ac-225 radiolabeled small molecules and antibodies for targeted alpha therapy, and preparation of Zr-89 labeled biomolecules for PET. Prior to his current position at the NCI, Dr. King conducted his doctoral thesis work at Cornell University, under the supervision of Prof. Justin Wilson. Dr. King’s thesis work focused on the preparation of inorganic and organometallic complexes of cobalt and rhenium as tumor microenvironment-targeting anticancer agents.